Loading company financials…
NEW YORK STOCK EXCHANGE, INC. · Health Care · CIK 0000010456
$25.65
+3.85% · live
Updated
$13.12B market value
From BAXTER INTERNATIONAL INC's FY2025 10-K, filed Feb 12, 2026 · read the filing
BAXTER INTERNATIONAL makes medical devices and equipment. It took in $11.24B last year, which makes it a large company. It spends more than it earns — losing about 9 cents on every dollar of sales.
The financial picture is led by accounting, with growth worth watching, while profitability and debt remain weak.
A conclusion from the filings, not a recommendation. Detailed figures and supporting evidence appear in their dedicated sections below.
Financial health
A mixed picture — some clear strengths and some weaknesses.
From BAXTER INTERNATIONAL INC's FY2025 annual filing · share price scored separately
Largest year-over-year changes in FY2025
Operating income
$14.0M → -$308.0M
Profit
-$649.0M → -$957.0M
Free cash flow
$573.0M → $332.0M
Earnings per share
-$1.28 → -$1.87
Measured against FY2024, from the 10-K filed Feb 12, 2026
Deteriorated: turned negative
$14.0M to -$308.0MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Deteriorated: $308.0M wider
-$649.0M to -$957.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
How the latest move compares (quote live), and what was published around it
BAX rose 3.85% on the latest quote. The average Health Care company tracked here moved +1.56%, and the S&P 500 −1.04%. That is 2.3 points above its sector and 4.9 points above the market.
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
Opinions from 19 analysts covering this company, as of . Their views, not this site's.
Of 19 analysts publishing on this company, 1 say strong buy, 4 say buy and 14 say hold. Analysts are paid to publish a view and are wrong often; the split above says how much they agree with each other, which is the part a single headline rating hides.
Published by Finnhub. Analyst coverage skews towards larger companies and towards optimism — sell ratings are rare across the whole market, so a company with none is ordinary rather than endorsed.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $957.0M last year, losing about 9 cents on every dollar of sales.
Slowly. Sales grew 5.7% last year.
Yes. Clearing its debt would take roughly 8.8 years of cash flow. For every $1 it owes, it owns $1.44 in assets. Its operating profit does not cover its interest bill — -1.06x against the interest it owes.
Core operating and valuation reference metrics
Whether the dividend is covered by what the business actually earns
It paid a dividend while making a loss, so the payment did not come out of profits — it came from reserves, borrowing or asset sales. It paid out 41% of the cash its operations generated. It has paid in each of the last 12 years.
WeakNext payment expected around , projected from how regularly it has paid before rather than from a date the company has announced.
Figures from the FY2025 annual filing
Last year it lost $957.0M and generated $845.0M of cash from operations.
Reported annual figures
As reported to the SEC, in USD. Hover or show sources to see where each figure came from.
| Income statement | FY202510-K · Feb 12, 2026Filing for FY2025 | FY202410-K · Feb 21, 2025Filing for FY2024 | FY202310-K · Feb 21, 2025Filing for FY2023 | FY202210-K · Feb 21, 2025Filing for FY2022 | FY202110-K · Feb 8, 2024Filing for FY2021 | ChangeFY2025 vs FY2024 |
|---|---|---|---|---|---|---|
| RevenueWhat is this? | $11.24B | $10.64B | $10.36B | $10.06B | $12.15B | +5.7% |
| Cost of revenue | $7.87B | $6.65B | $6.21B | $6.51B | $7.43B | +18.2% |
| Gross profit | $3.38B | $3.98B | $4.15B | $3.55B | $4.72B | −15.2% |
| Gross marginGross profit ÷ revenueWhat is this? | 30.1% | 37.5% | 40.1% | 35.3% | 38.9% | −7.4 pts |
| Selling, general and administrative | $2.89B | $2.97B | $2.95B | $3.10B | $2.85B | −2.6% |
| Operating income | -$308.0M | $14.0M | $707.0M | -$2.85B | $1.35B | n/m |
| Operating marginOperating income ÷ revenueWhat is this? | -2.7% | 0.1% | 6.8% | -28.3% | 11.1% | −2.9 pts |
| Interest expense | $290.0M | $408.0M | $508.0M | $413.0M | $207.0M | −28.9% |
| Income before tax | -$505.0M | -$289.0M | $242.0M | -$3.25B | $1.12B | −74.7% |
| Net income | -$957.0M | -$649.0M | $2.66B | -$2.43B | $1.28B | −47.5% |
| Net marginNet income ÷ revenueWhat is this? | -8.5% | -6.1% | 25.6% | -24.2% | 10.6% | −2.4 pts |
| Earnings per shareNet income ÷ shares outstanding at the period end — close to, but not the same as, the reported EPSWhat is this? | $-1.87 | $-1.28 | $5.26 | $-4.84 | $2.54 | −46.4% |
† calculated from other reported figures, such as total liabilities as assets minus equity.
This company's latest filing beside its peers' stored scores
| Company | Health | F-Score | Revenue growth | Profit margin | P/E | Debt to equity |
|---|---|---|---|---|---|---|
| BAXBAXTER INTERNATIONAL INC · this page | 5.0/10 | 6/9 | 5.7% |
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Officers, directors and major shareholders must report within two business days of a trade.
Had shares withheld to cover taxes — 2,098 shares at $25.70 ($53.9K)
Holds 29,164 shares after this filing.
Had shares withheld to cover taxes — 54,276 shares at $25.70 ($1.4M)
Holds 518,447 shares after this filing.
20 recent filings, newest first. Each is labelled from its form and item numbers, not from its wording.
Had a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingSigned a material agreement · Reported another event
Read the filingWrite down why you are following BAXTER INTERNATIONAL INC, what has to go right and what would change your mind, then see each new annual report measured against it. Sign in to start one.
Go deeper
Every figure above traces back to a filing in the timeline, each linked to the document itself.
Coverage from the last 30 days
Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for
Yahoo ·
Why Baxter (BAX) Stock Is Down Today
Yahoo ·
S&P 500 Top Movers: EFX and HAS Lead Today's Gainers, GM and DVA Fall
ChartMill ·
S&P 500 Unusual Volume Movers for October 20
ChartMill ·
S&P 500 Top Movers: Gainers and Losers From Today's US Session
ChartMill ·
Every company's figures are checked for internal consistency: the balance sheet adding up, figures sharing one currency, cash flow and share counts within plausible ranges, and how recent the latest annual report is. Nothing here changes a figure.
Financial figures are from BAX's 10-K for fiscal year 2025 (period ending 2025-12-31, filed Feb 12, 2026), reported under the US GAAP taxonomy. View the source filing.
4 of 4 scored areas had enough reported figures to judge
The score averages profitability, growth, debt and accounting. All four had enough reported figures. Cash generation is shown for context and already feeds profitability. Valuation is scored separately, because a share price says nothing about whether the business is sound. 9 of the 9 Piotroski checks could be evaluated. How the score works
Each year scored only from its annual report as it was first filed
| Fiscal year | Health | F-Score | Scored from |
|---|---|---|---|
| FY2025 | 5.0 | 6/9 | 10-K, filed Feb 12, 2026 |
| FY2024 | 5.0 | 4/9 | 10-K, filed Feb 21, 2025 |
| FY2023 | 7.0 | 6/9 | 10-K, filed Feb 8, 2024 |
| FY2022 | 6.0 | 4/9 | 10-K, filed Feb 9, 2023 |
| FY2021 | 6.0 | 6/9 | 10-K, filed Feb 23, 2022 |
| FY2020 | 8.0 | 6/9 | 10-K, filed Feb 11, 2021 |
A later restatement never reaches back into an earlier year, and every year is scored without a share price, so the latest point can differ a little from the headline score, which uses today's price.
Every check behind the three models, and what each one tests
6 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
2.26
In the grey zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-2.62
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Deteriorated: -42.1%
$573.0M to $332.0MCritical
Why it matters: Cash left after paying for the plant that produced it — the money genuinely available for dividends, buybacks or paying down debt. Harder to flatter than profit.
Deteriorated: $0.59 wider
-$1.28 to -$1.87Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Changed: -41.0%
$590.0M to $348.0MCritical
Why it matters: Cash handed to shareholders. A rise can be a higher dividend or simply more shares, and a cut is a decision the company explains in its own filing — neither is rated here.
Deteriorated: -15.2%
$3.98B to $3.38BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Deteriorated: −7.4 pts
37.5% to 30.1%Significant
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: -28.4%
$13.18B to $9.44BSignificant
Why it matters: Rising debt is not automatically bad — borrowing to build something that earns more than the interest is ordinary. It matters when it grows faster than the profit meant to service it.
Changed: +15.0%
$446.0M to $513.0MSignificant
Why it matters: Neither good nor bad on its own. Heavy spending is a company building capacity or a company struggling to stand still, and the two look identical in this figure.
Improved: +5.7%
$10.64B to $11.24BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Deteriorated: −2.9 pts
0.1% to -2.7%Notable
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Deteriorated: −2.4 pts
-6.1% to -8.5%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +11.5%
$1.76B to $1.97BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Q2 FY2026 against Q2 FY2025, from the 10-Q filed Jul 30, 2026 — read it.
Improved: +38.5%
$91.0M to $126.0MSignificant
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: +37.4%
$0.18 to $0.24Significant
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +27.5%
$1.69B to $2.15BSignificant
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
Improved: +5.3%
$2.81B to $2.96BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +13.6%
$191.0M to $217.0MNotable
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: +1.0 pts
3.2% to 4.3%Notable
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Q2 FY2026 against Q1 FY2026, from the 10-Q filed Jul 30, 2026 — read it. Quarter-to-quarter moves include seasonal swings — a retailer's holiday quarter — which the year-earlier comparison removes.
Improved: +228.8%
$66.0M to $217.0MCritical
Why it matters: Profit from running the business, before interest and tax. Less exposed than profit to one-off financing and tax items, so a clearer read on the business itself.
Improved: turned positive
-$15.0M to $126.0MCritical
Why it matters: Profit swings far more than sales do, and one-off items — a legal settlement, a tax charge, an asset sale — move it without the underlying business changing.
Improved: turned positive
-$0.03 to $0.24Critical
Why it matters: Profit divided by the shares in issue at the period end, so it sits close to but not on the company's own reported figure. It can rise with no growth in profit when the company buys back stock — read it beside the share count.
Improved: +15.8%
$891.0M to $1.03BSignificant
Why it matters: What is left of sales after the direct cost of producing them. It normally moves with revenue, so a move out of step with revenue is the part worth noticing.
Improved: +4.9 pts
2.4% to 7.3%Significant
Why it matters: What survives each sale after running the business. A falling operating margin beside a steady gross margin points at overheads — wages, marketing, research — rather than pricing.
Improved: +4.8 pts
-0.6% to 4.3%Significant
Why it matters: What survives to the very end of each sale. Worth reading beside revenue: growing sales on a shrinking margin means the company is buying its growth.
Improved: +9.6%
$2.70B to $2.96BNotable
Why it matters: Sales are what everything else is built on. A fall can be lost customers, lower prices, or a business the company sold — the filing itself says which.
Improved: +1.9 pts
33.0% to 34.9%Notable
Why it matters: What survives each sale before overheads. Falling gross margin usually means the company is discounting or its input costs rose — it is the earliest place pricing pressure shows.
Improved: +6.6%
$2.02B to $2.15BNotable
Why it matters: A falling cash pile is only a warning if the company is consuming it. Paying down debt, buying back stock and paying a dividend all reduce cash by choice.
1 other measure barely moved. Figures compare the two most recent annual filings — read the latest one. Moves are graded on fixed lines — 5%, 15% and 40% for amounts, and 1, 3 and 8 points for margins — as notable, significant or critical. Nothing here reads the management commentary, which is where a company explains its own numbers.
These coincide with the move in time. None is presented as its cause: a price can move on news that names no company, on the wider market, or on trading that no document records.
Filter by minute, hour, day or week — or compare against peers
Loading price history…
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 4.8% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
The trailing P/E is 84.1x — a high multiple relative to the current trailing profit.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
| -8.5% |
| — |
| 2.28x |
| RMDRESMED INC | 9.0/10 | 8/9 | 9.9% | 26.9% | 23.96x | 0.36x |
|---|
| DXCMDEXCOM INC | 8.7/10 | 7/8 | 15.6% | 17.9% | 36.04x | 1.31x |
|---|
| ZBHZIMMER BIOMET HOLDINGS, INC. | 7.0/10 | 5/9 | 7.2% | 8.6% | 27.90x | 0.82x |
|---|
| PODDINSULET CORP | 8.7/10 | 7/9 | 30.7% | 9.1% | 42.19x | 1.11x |
|---|
| Median of peers | 8.7/10 | — | 12.7% | 13.5% | 31.97x | 0.96x |
|---|
Peers come from the company's industry classification. A difference describes the companies; it does not rank them.
Had shares withheld to cover taxes — 750 shares at $25.48 ($19.1K)
Holds 30,370 shares after this filing.
Estimated from how often this has happened before, not a confirmed date.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Had a director or senior officer leave or join
Reported another event
Read the filingQuarterly report for Q2 FY2026
Revenue +5.3% · Profit margin +1.0 pts · Profit +38.5% — against Q2 FY2025
Read the filingPublished results · Reported another event
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Amended its charter or changed its financial year · Held a shareholder vote
Read the filingQuarterly report for Q1 FY2026
Profit margin −5.4 pts · Profit turned negative · Earnings per share turned negative — against Q1 FY2025
Read the filingPublished results · Reported another event
Read the filingProxy statement for a shareholder meeting
Read the filingMade a Regulation FD disclosure
Read the filingHad a director or senior officer leave or join · Made a Regulation FD disclosure
Read the filingAnnual report for FY2025
Revenue +5.7% · Operating margin −2.9 pts · Operating income turned negative — against FY2024
Read the filingHad a director or senior officer leave or join · Published results · Reported another event
Read the filingReported another event
Read the filingSigned a material agreement · Terminated a material agreement · Took on a direct financial obligation · Reported another event
Read the filingSigned a material agreement
Read the filingReported another event
Read the filingReported another event
Read the filingPrimary sources and further research